Analysis of paraoxonase 1 (PON1) genetic polymorphisms and activities as risk factors for ischemic stroke in Turkish population

Cell Biochemistry and Function

Volumn 27, Issue 8, 2009, Pages 558-567

  Can Demirdöǧen, Birsen ^a   Demirkaya, Şeref ^b   Türkanoǧlu, Aysun ^a   Bek, Semai ^b   Arinç, Emel ^a   Adali, Orhan ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Genotype; Paraoxonase; Polymorphism; PON1; Stroke

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CYSTEINE; DIAZOXONASE; ESTERASE; GLUTAMINE; LEUCINE; METHIONINE; THREONINE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION MAPPING; RISK FACTOR; SPECTROPHOTOMETRY; TURKISH;

AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STROKE; TURKEY;

EID: 71949122972     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1607     Document Type: Article

References (48)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924. (Pubitemid 19101597)
2. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473.
3. Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin in Lipidol 2000; 11(4): 383-388. (Pubitemid 30616096)
4. Gan KN, Smolen A, Eckerson H, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19: 100-106.
5. Hassett C, Richter RJ, Humbert R, et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 1991; 30: 10141-10149.
6. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a highaffinity, saturable, desorption mechanism. J Biol Chem 2002; 277(6): 4301-4308. (Pubitemid 34968695)
7. Blatter M-C, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-85: identity of K-85 with paraoxonase. Eur J Biochem 1993; 211: 871-879. (Pubitemid 23050064)
8. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 2004; 369(1): 78-88.
9. Mackness MI. Possible medical significance of human serum paraoxonase. In Enzymes Hydrolysing Organophosphorus Compounds, Reigner E, Aldridge WN, Hoskin FCG (eds). Ellis-Horwood: Chichester, 1989; 202-213.
10. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154.
11. Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115: 243-253.
12. Rosenblat M, Gaidukov L, Khersonsky O, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006; 281(11): 7657-7665. (Pubitemid 43847536)
13. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590. (Pubitemid 28198486)
14. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 2001; 354: 1-7. (Pubitemid 32183437)
15. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275: 3957-3962. (Pubitemid 30094622)
16. Josse D, Bertels C, Lockidge O, Masson P. PON1 structure. In Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects, Costa LG, Furlong CE (eds). Kluwer Acad: Norwell; MA, 2002; 27-52.
17. Shih DM, Gu L, Xia Y-R, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-287. (Pubitemid 28335041)
18. Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 2002; 290(3): 921-927. (Pubitemid 34687449)
19. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet 1996; 14: 334-336.
20. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9: 745-753.
21. Brophy VH, Jarvik GP, Furlong CE. PON1 polymorphisms. In Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects, Costa LG, Furlong CE (eds). Kluwer Acad: Norwell, MA, 2002; 53-77.
22. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase gene (PON1) expression. Am J Hum Genet 2001; 68: 1428-1436.
23. Weitman SD, Vodicnick MJ, Lech TJ. Influence of pregnancy on parathion toxicity and disposition. Toxicol Appl Pharmacol 1983; 71: 215-224.
24. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15(11): 1812-1818.
25. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis (CAS) reduces common carotid intima-media thickness (IMT), blood pressure and LDL oxidation. Clin Nutr 2004; 23: 423-433. (Pubitemid 38811681)
26. Tomás M, Sentì M, Garcia-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000; 20: 2113-2119. (Pubitemid 30694845)
27. Imai Y, Morita H, Kurihara H, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000; 149: 435-442. (Pubitemid 30145555)
28. Ueno T, Shimazaki E, Matsumoto T, et al. Paraoxonase1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population. Med Sci Monit 2003; 9(6): CR260-264.
29. Ranade K, Kirchgessner TG, Iakoubova OA, et al. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005; 36(11): 2346-2350. (Pubitemid 41566956)
30. Baum L, Ng HK, Woo KS, et al. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem 2006; 39(3): 191-195.
31. Pasdar A, Ross-Adams H, Cumming A, et al. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet 2006; 7: 28.
32. Voetsch B, Benke KS, Panhuysen CI, Damasceno BP, Loscalzo J. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol 2004; 61(3): 351-356. (Pubitemid 38327352)
33. Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-2447.
34. Aydin M, Gencer M, Cetinkaya Y, et al. PON1 55/192 polymorphism, oxidative stress, type, prognosis and severity of stroke. IUBMB Life 2006; 58(3): 165-172. (Pubitemid 43786042)
35. Kim NS, Kang K, Cha MH, et al. Decreased paraoxonase-1 activity is a risk factor for ischemic stroke in Koreans. Biochem Biophys Res Commun 2007; 364(1): 157-162. (Pubitemid 47599458)
36. Can Demirdöǧen B, Türkanoǧlu A, Bek S, et al. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 2008; 41(1-2): 1-9.
37. 2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet 1993; 31(7-8): 321-328.
38. Campo S, Sardo MA, Trimarchi G, et al. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol 2004; 39: 1089-1094.
39. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988; 43: 230-238.
40. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138.
41. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase alloenzymes Q and R. Arterioscler Thromb Vasc Biol 1998; 10: 1617-1624. (Pubitemid 28465415)
42. Schmidt H, Schmidt R, Niederkorn K, et al. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 1998; 29: 2043-2048. (Pubitemid 28443515)
43. Fortunato G, Rubba P, Panico S, et al. A paraoxonase gene polymorphism, PON 1 (55) as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis 2003; 167(1): 141-148.
44. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase- 1. Clin Sci 2004; 107: 435-447.
45. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20: 516-521. (Pubitemid 30086111)
46. O'Leary KA, Edwards RJ, Town MM, Boobis AR. Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. Pharmacogenet Genomics 2005; 15(1): 51-60.
47. Leviev I, Righetti A, James RW. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 2001; 79: 457-463. (Pubitemid 32757471)
48. Shih DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97: 1630-1639. (Pubitemid 26105474)